International Journal of Epidemiology 2003;32:161-162
© International Epidemiological Association 2003
Letters to the Editor |
Is all-cause mortality a useful epidemiological endpoint in vaccine trials? An example of BCG (Bacille-Calmette-Guerine)
Department of Respiratory Medicine, University of Dublin (Trinity College), St Jamess Hospital, Dublin 8, Ireland. E-mail: kabirz@tcd.ie
| The first 10% of the full text of this article appears below. |
SirsSince 1978, the WHO/UNICEF Expanded Programme on Immunization has led to steady reductions in childhood mortality from the vaccine preventable diseases both in developed and less-developed nations. Surprisingly, scant attention has been paid to the overall effect of routine vaccines. In general, we have taken vaccines and schedules that are effective in developed nations with low levels of child mortality and used them in high mortality populations without studying their effects on all-cause mortality.
As early as the mid-1970s, measles vaccination showed an overall improvement in the probability of child survival,
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. Roth, P. Gustafson, A. Nhaga, Q. Djana, A. Poulsen, M.-L. Garly, H. Jensen, M. Sodemann, A. Rodriques, and P. Aaby BCG vaccination scar associated with better childhood survival in Guinea-Bissau Int. J. Epidemiol., June 1, 2005; 34(3): 540 - 547. [Abstract] [Full Text] [PDF] |
||||
